Nuvelo Appoints Jan Johansson, MD, PhD, to Lead Clinical Affairs
Monday June 9, 9:30 am ET
SUNNYVALE, Calif., June 9 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: NUVO - News), today announced the appointment of Jan Johansson, M.D., Ph.D., as chief medical officer and vice president, clinical affairs. Dr. Johansson joins Nuvelo as a member of the senior management team and will be responsible for Nuvelo's clinical affairs activities.
ADVERTISEMENT
"With our lead product candidate, alfimeprase, moving rapidly through the clinic and the promise of additional candidates emerging from our secreted protein and immunotherapeutic programs, we sought to strengthen our clinical development capabilities," said Dr. Ted W. Love, president and chief executive officer of Nuvelo. "Dr. Johansson provides this expertise, bringing both an excellent academic research background and relevant industry experience needed to strengthen both our current and future clinical development programs."
Dr. Johansson brings to Nuvelo over 16 years of experience as a practicing physician in internal medicine and cardiology and 14 years of experience in academic medicine including work in atherosclerosis studies, drug intervention trials, multi-center, multi-international trials and he has published more than 50 peer reviewed scientific articles.
Prior to joining Nuvelo, Dr. Johansson served the pharmaceutical industry in various vice president positions in both public and private biotechnology companies, conducting several clinical trials in all phases of development and preparing the corresponding regulatory documents. Most recently he served as vice president, clinical research and development for Lipid Sciences, Inc. and was co-founder, vice president, clinical affairs and senior clinical research fellow of Esperion Therapeutics, Inc. From 1995 to 1997, Dr. Johansson was a medical adviser with executive responsibilities at Pharmacia, working in clinical research and thrombosis.
Dr. Johansson earned his M.D. and Ph.D. at the Karolinska Institute in Sweden and subsequently became associate professor at the Karolinska Hospital before joining the pharmaceutical industry in 1995.
About Nuvelo
Nuvelo, Inc., formed by the merger of Hyseq Pharmaceuticals, Inc. and VARIAGENICS, Inc., is engaged in the discovery, development and commercialization of life improving therapeutics for the treatment of human disease. Nuvelo's lead product candidate, alfimeprase, is partnered with Amgen and is currently conducting a Phase II trial in catheter occlusion. A second Phase II trial in peripheral arterial occlusion is scheduled to begin in the first half of 2003. Additional programs include drug discovery focused on immunotherapeutics and secreted proteins.
Information about Nuvelo is available at our new Web site at www.nuvelo.com or by phoning 408-215-4000.
Statements contained in this press release which are not historical in nature, are intended to be, and are hereby identified as "forward-looking statements" for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as "believe," "expect," "anticipate," "should," "may," "estimate," "goals," and "potential," among others. Such statements are based on our management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the risk that we may not successfully integrate the VARIAGENICS business following our recent merger, uncertainties relating to drug discovery, clinical development processes and the development and commercialization of our molecular diagnostics technology, changes in relationships with strategic partners and dependence upon strategic partners for the performance of critical activities under collaborative agreements, the impact of competitive products and technological changes, uncertainties relating to patent protection and regulatory approval and uncertainties relating to our ability to obtain substantial additional funds required for progress in drug discovery and development. These and other factors are identified and described in more detail in Nuvelo, Hyseq and VARIAGENICS filings with the SEC, including and without limitation, Nuvelo's annual report on Form 10-K and the related Form 10-K/A for the year ended December 31, 2002. We disclaim any intent or obligation to update these forward-looking statements.
--------------------------------------------------------------------------------
Source: Nuvelo, Inc. |
